Cargando…

Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437881/ https://www.ncbi.nlm.nih.gov/pubmed/16623613 http://dx.doi.org/10.18553/jmcp.2006.12.3.265

Ejemplares similares

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

Safety of meloxicam oral provocation challenge in patients with NSAID reaction
por: Morales, Cristina Isabel Herrera, et al.
Publicado: (2015)

Repeated administration of the NSAID meloxicam alters the plasma and urine lipidome
por: Rivera-Velez, Sol M., et al.
Publicado: (2019)

Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
por: Rostom, Alaa, et al.
Publicado: (2009)

The Cox-2 Inhibitor Meloxicam Ameliorates Neuroinflammation and Depressive Behavior in Adult Mice after Splenectomy
por: Haile, Michael, et al.
Publicado: (2016)

Step-Therapy Edits for PPIs and COX-2 Drugs - What We Do and Do Not Know
por: Curtiss, Frederic R.
Publicado: (2004)

Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007)

Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
por: Borer, Jeffrey S, et al.
Publicado: (2005)

Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs
por: Scheiman, James M, et al.
Publicado: (2005)

Synthesis, Spectroscopic and Biological Investigation of a New Ca(II) Complex of Meloxicam as Potential COX-2 Inhibitor
por: Samra, Malka M., et al.
Publicado: (2022)

Selective COX-2 inhibitor continues to be a safe alternative in patients with nonselective NSAIDs hypersensitivity
por: Thalappil, Sherin, et al.
Publicado: (2022)

New NSAID Conjugates as Potent and Selective COX-2 Inhibitors: Synthesis, Molecular Modeling and Biological Investigation
por: Bokhtia, Riham M., et al.
Publicado: (2023)

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk
por: Cheng, I, et al.
Publicado: (2007)

Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus)
por: Dhondt, Laura, et al.
Publicado: (2017)

Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
por: Zhou, Yinghong, et al.
Publicado: (2020)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury
por: Yang, Man, et al.
Publicado: (2015)

Measuring Value in the Treatment of Symptoms of Allergic Rhinitis With Nasal Steroids
por: Curtiss, Frederic R.
Publicado: (2006)

Gastrointestinal Bleeding Rates Among Managed Care Patients Newly Started on COX-2 Inhibitors or Nonselective NSAIDs
por: Stockl, Karen, et al.
Publicado: (2005)

A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
por: Takami, Yuko, et al.
Publicado: (2016)

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis
por: Latimer, Nicholas, et al.
Publicado: (2009)

Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways
por: Dong, Xiaofeng, et al.
Publicado: (2014)

An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
por: Parkinson, Lynne, et al.
Publicado: (2011)

COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred
por: Day, Richard
Publicado: (2003)

Looking for the Outcomes We Love in All the Wrong Places: The Questionable Value of Biomarkers and Investments in Chronic Care Disease Management Interventions
por: Curtiss, Frederic R.
Publicado: (2008)

Best Value for Money in Triptans
por: Curtiss, Frederic R.
Publicado: (2005)

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006)

NSAIDs, are they dangerous for pancreatic surgery?
por: Lee, Ji-Hyun
Publicado: (2022)

The importance of provocation tests with COX2 inhibitors on patients with a history of cross-hypersensitivity to non-steroidal anti-inflammatory (NSAIDs)
por: Gonçalves, Tania Tavares
Publicado: (2015)

Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Value for Money in Disease Management of Benign Prostatic Hyperplasia
por: Curtiss, Frederic R.
Publicado: (2004)

OTC Omeprazole for Your Heartburn - Enormous Value-for-Money Opportunity
por: Curtiss, Frederic R.
Publicado: (2004)

Making the World Safe for Evidence-Based Policy: Let's Slay the Biases in Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Market Withdrawal of Vioxx: Is it Time to Retihink the Use of COX-2 Inhibitors?
por: Ortiz, Eduardo
Publicado: (2004)

NSAID choice: lessons from PRECISION
por: Reed, Grant W., et al.
Publicado: (2019)

Still Looking for Health Outcomes in All the Wrong Places? Misinterpreted Observational Evidence, Medication Adherence Promotion, and Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Value for Money in Disease Management of Acute Coronary Syndrome - The Price of Aspirin to Reduce the Costs of ACS
por: Curtiss, Frederic R.
Publicado: (2005)

PandT Committees - Black Boxes Versus AMCP Format, and What Is the True Cost and Value of Pimecrolimus
por: Curtiss, Frederic R.
Publicado: (2005)

Pressure on Pharmacy Benefit Managers for Disclosure and Demonstration of Value - Rebates and Drug Benegit Cost Savings
por: Curtiss, Frederic R.
Publicado: (2003)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_p1i7jc2t7p3e2e1qobq4vd2eql